Globus Medical (GMED)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Research Workspace
Put GMED beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue growth to at least $3.18B in FY26: FY26 revenue guidance $3.18B-$3.22B vs $3.18B target.
View ThesisRevenue growth is accelerating — up about 20% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 13%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskGMED's revenue growth must continue to justify its current valuation. Revenue guidance for FY26 is $3.18B-$3.22B, which aligns with recent strong performance. GMED trades at 16× P/E versus a peer median of 28×, indicating it looks cheap on this basis. The primary risk is a potential credibility hit if GMED cuts guidance after recently raising it. Peer multiples imply a price about 30% above where it trades. Our read remains intact.
Trailing returns as of 2026-09-04. GMED is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering GMED (as of Sep 2026).
Based on 8 Wall Street analysts offering 12-month price targets for GMED in the last 4 months.
Continue this research
Compare GMED with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GMED Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put GMED next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain and update full-year 2026 revenue and EPS guidance
Analysts trimming growth views impacts revenue and EPS guidance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $78.29
The last 12 months of price, then the range of analyst 12-month targets from today’s $78.29.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Increase net income and earnings per share
Record EPS and margin expansion support growth objectives.

Advances: Maintain and update full-year 2026 revenue and EPS guidance
Reaffirms guidance for revenue and EPS, supporting growth objectives.

Advances: Increase revenue growth
Beating sales expectations supports revenue growth objective.
Advances: Increase revenue growth
Topping revenue forecast supports growth objectives.
